Retinal toxicity/biocompatibility of medical devices in direct contact with the retina is an important subject for clinicians and scientists. As these effects are not very frequent, there is also a relative lack of information for many clinicians. The past has taught us multiple times that there is a significant safety problem associated with severe loss of vision in affected patients. In this review, we want to classify medical products that are used in the back of the eye, describe recent examples of toxicity, critically reflect on the regulations that exist and suggest improvements that can be done to ensure patient safety without hindering innovation. Methods: Critical review of the recent papers and personal experience of the authors in this issue. Medical devices used in the back of the eye and recent examples of toxicity are described, regulations that exist are critically reflected and improvements suggested that can ensure patient safety without hindering innovation. Results: There is clear evidence of toxicity after intraocular surgery in any category. Some cytotoxic indirect methods have failed in detecting this toxicity. Some ISO rules do not seem appropriate. Postmarketing safety is missing. There is little data on this issue. Conclusions: The absence of a clear regulation of the production, purification and evaluation of the toxic effects of the medical devices supposes the possibility that products are not sufficiently safe to obtain the CE mark.

Keywords:
Retinal toxicity, Toxicity testing, Vitrectomy, Silicone oil toxicity, Heavy liquid toxicity, Vital dye toxicity, Intraocular surgery medical devices, ISO 10993 norm
1.
Machemer R, Buettner H, Norton EW, Parel JM: Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol 1971; 75: 813–820.
2.
Machemer R: Subtotal vitrectomy through the pars plana. Trans Am Acad Ophthalmol Otolaryngol 1973; 77:OP198–OP201.
3.
Kelly NE, Wendel RT: Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol 1991; 109: 654–659.
4.
Eckardt C: Transconjunctival sutureless 23-gauge vitrectomy. Retina 2005; 25: 208–211.
5.
de Oliveira PRC, Berger AR, Chow DR: Vitreoretinal instruments: vitrectomy cutters, endoillumination and wide-angle viewing systems. Int J Retina Vitreous 2016; 2: 28.
6.
Park DW, Sipperley JO, Sneed SR, Dugel PU, Jacobsen J: Macular hole surgery with internal-limiting membrane peeling and intravitreous air. Ophthalmology 1999; 106: 1392–1397; discussion 1397–1398.
7.
Marco-Gomariz MA, Hurtado-Montalban N, Vidal-Sanz M, Lund RD, Villegas-Perez MP: Phototoxic-induced photoreceptor degeneration causes retinal ganglion cell degeneration in pigmented rats. J Comp Neurol 2006; 498: 163–179.
8.
Manzanas L, Pastor C, Munoz R, Girbes T: Intraocular irrigating solutions and vitrectomy-related changes (in protein, lactic and ascorbic acid) in rabbit vitreous. Ophthalmic Res 1992; 24: 61–67.
9.
Minami M, Oku H, Okuno T, Fukuhara M, Ikeda T: High infusion pressure in conjunction with vitreous surgery alters the morphology and function of the retina of rabbits. Acta Ophthalmol Scand 2007; 85: 633–639.
10.
Hasumura T, Yonemura N, Hirata A, Murata Y, Negi A: Retinal damage by air infusion during vitrectomy in rabbit eyes. Invest Ophthalmol Vis Sci 2000; 41: 4300–4304.
11.
Lüke M, Januschowski K, Beutel J, Warga M, Grisanti S, Peters S, et al: The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res 2008; 87: 22–29.
12.
Januschowski K, Mueller S, Spitzer MS, Schramm C, Doycheva D, Bartz-Schmidt KU, et al: Evaluating retinal toxicity of a new heavy intraocular dye, using a model of perfused and isolated retinal cultures of bovine and human origin. Graefes Arch Clin Exp Ophthalmol 2012; 250: 1013–1022.
13.
Inoue M, Iriyama A, Kadonosono K, Tamaki Y, Yanagi Y: Effects of perfluorocarbon liquids and silicone oil on human retinal pigment epithelial cells and retinal ganglion cells. Retina 2009; 29: 677–681.
14.
Romano MR, Vallejo-Garcia JL, Parmeggiani F, Romano V, Vinciguerra P: Interaction between perfluorcarbon liquid and heavy silicone oil: risk factor for “sticky oil” formation. Curr Eye Res 2012; 37: 563–566.
15.
Morescalchi F, Costagliola C, Duse S, Gambicorti E, Parolini B, Arcidiacono B, et al: Heavy silicone oil and intraocular inflammation. Biomed Res Int 2014; 2014: 574825.
16.
Hurst J, Schnichels S, Spitzer MS, Bartz-Schmidt KU, Farecki M-L, Szurman P, et al: Negative effects of acid violet-17 and MBB dual in vitro on different ocular cell lines. Curr Eye Res 2017; 42: 1209–1214.
17.
Pastor JC, Coco RM, Fernandez-Bueno I, Alonso-Alonso ML, Medina J, Sanz-Arranz A, et al: Acute retinal damage after using a toxic perfluoro-octane for vitreo-retinal surgery. Retina 2017; 37: 1140–1151.
18.
Méndez-Martínez S, Calvo P, Rodriguez-Marco NA, Faus F, Abecia E, Pablo L: Blindness related to presumed retinal toxicity after using perfluorocarbon liquid during vitreoretinal surgery. Retina (Philadelphia) DOI: 10.1097/IAE.0000000000001783.
19.
Srivastava GK, Alonso-Alonso ML, Fernandez-Bueno I, Garcia-Gutierrez MT, Rull F, Medina J, et al: Comparison between direct contact and extract exposure methods for PFO cytotoxicity evaluation. Sci Rep 2018; 8: 1425.
20.
Kanda S, Uemura A, Yamashita T, Kita H, Yamakiri K, Sakamoto T: Visual field defects after intravitreous administration of indocyanine green in macular hole surgery. Arch Ophthalmol 2004; 122: 1447–1451.
21.
Cheng S-N, Yang T-C, Ho J-D, Hwang JF, Cheng C-K: Ocular toxicity of intravitreal indocyanine green. J Ocul Pharmacol Ther 2005; 21: 85–93.
22.
Stalmans P, Van Aken EH, Veckeneer M, Feron EJ, Stalmans I: Toxic effect of indocyanine green on retinal pigment epithelium related to osmotic effects of the solvent. Am J Ophthalmol 2002; 134: 282–285.
23.
Kernt M, Hirneiss C, Wolf A, Liegl R, Rueping J, Neubauer A, et al: Indocyanine green increases light-induced oxidative stress, senescence, and matrix metalloproteinases 1 and 3 in human RPE cells. Acta Ophthalmol 2012; 90: 571–579.
24.
Enaida H, Hisatomi T, Goto Y, Hata Y, Ueno A, Miura M, et al: Preclinical investigation of internal limiting membrane staining and peeling using intravitreal brilliant blue G. Retina 2006; 26: 623–630.
25.
Kawahara S, Hata Y, Miura M, Kita T, Sengoku A, Nakao S, et al: Intracellular events in retinal glial cells exposed to ICG and BBG. Invest Ophthalmol Vis Sci 2007; 48: 4426–4432.
26.
Remy M, Thaler S, Schumann RG, May CA, Fiedorowicz M, Schuettauf F, et al: An in vi vo evaluation of Brilliant Blue G in animals and humans. Br J Ophthalmol 2008; 92: 1142–1147.
27.
Gerding H: Acid Violet 17: a new dye for chromovitrectomy? Klin Monbl Augenheilkd 2016; 233: 460–464.
28.
Röhrig S, Farecki M-L, Boden K, et al: Negative effects of vital dyes after uneventful vitreomacular surgery. Retina DOI: 10.1097/IAE.0000000000002231.
29.
Peyman GA, Schulman JA, Sullivan B: Perfluorocarbon liquids in ophthalmology. Surv Ophthalmol 1995; 39: 375–395.
31.
Pradeep S, Chhablani JK, Patel B, Rani P: Delayed inflammation associated with retained perfluorocarbon liquid. Indian J Ophthalmol 2011; 59: 396.
32.
Figueroa MS, Casas DR: Inflammation induced by perfluorocarbon liquid: intra- and postoperative use. BioMed Res Int 2014; 2014: 907816.
33.
Lee GA, Finnegan SJ, Bourke RD: Subretinal perfluorodecalin toxicity. Aust NZJ Ophthalmol 1998; 26: 57–60.
34.
Osterholz J, Winter M, Winkler J, Pfister G, Kovacs G, Dresp J, et al: Retinal damage by perfluorocarbon liquids – a question of specific gravity? Intraocular pressure peaks and shearing forces (in German). Klin Monbl Augenheilkd 2009; 226: 38–47.
35.
Mikhail MA, Mangioris G, Best RM, McGimpsey S, Chan WC: Management of giant retinal tears with vitrectomy and perfluorocarbon liquid postoperatively as a short-term tamponade. Eye (Lond) 2017; 31: 1290–1295.
36.
Veckeneer MA, de Voogd S, Lindstedt EW, Menz D-H, van Meurs JC: An epidemic of sticky silicone oil at the Rotterdam Eye Hospital. Patient review and chemical analyses. Graefes Arch Clin Exp Ophthalmol 2008; 246: 917–922.
37.
Savion N, Alhalel A, Treister G, Bartov E: Role of blood components in ocular silicone oil emulsification. Studies on an in vitro model. Invest Ophthalmol Vis Sci 1996; 37: 2694–2699.
38.
Champion R, Faulborn J, Bowald S, Erb P: Peritoneal reaction to liquid silicone: an experimental study. Graefes Arch Clin Exp Ophthalmol 1987; 225: 141–145.
39.
de Queiroz JMJ, Blanks JC, Ozler SA, Alfaro DV, Liggett PE: Subretinal perfluorocarbon liquids. An experimental study. Retina 1992; 12:S33–S39.
40.
Williams RL, Day M, Garvey MJ, English R, Wong D: Increasing the extensional viscosity of silicone oil reduces the tendency for emulsification. Retina 2010; 30: 300–304.
41.
Stalmans P, Pinxten A-M, Wong DS: Cohort safety and efficacy study of siluron2000 emulsification-resistant silicone oil and F4h5 in the treatment of full-thickness macular hole. Retina (Philadelphia) 2015; 35: 2558.
42.
Pralits JO, Repetto R, Nepita I, Romano MR, Ravera F, Santini E, et al: The effect of albumin on the interfacial tension of silicone oil in vitrectomized eyes. Invest Ophthalmol Vis Sci 2017; 58: 5006–5006.
43.
Pastor JC, Zarco JM, Del Nozal MJ, Pampliega A, Marinero P: Clinical consequences of the use of highly purified silicone oil. Comparative study of highly and less purified silicone oil. Eur J Ophthalmol 1997; 8: 179–183.
44.
Dresp JH, Menz D-H: Preparation and processing of vitreoretinal instrumentation and equipment as a risk factor for silicone oil emulsification. Retina 2004; 24: 110–115.
45.
Friberg TR, Siska PE, Somayajula K, Williams J, Eller AW: Interactions of perfluorocarbon liquids and silicone oil as characterized by mass spectrometry. Graefes Arch Clin Exp Ophthalmol 2003; 241: 809–815.
46.
Romano MR, Zenoni S, Arpa P, Mariotti C: Mixture of ether and silicone oil for the treatment of inferior complicated retinal detachment. Eur J Ophthalmol 2013; 23: 230–235.
47.
French-Mowat E, Burnett J: How are medical devices regulated in the European Union? J R Soc Med 2012; 105(suppl 1):S22–S28.
48.
Schultheiss M, Schnichels S, Hermann T, Hurst J, Feldkaemper M, Arango-Gonzalez B, et al: Hypothermia protects and prolongs the tolerance time of retinal ganglion cells against ischemia. PLoS One 2016; 11:e0148616.
49.
Roider J, Hoerauf H, Kobuch K, Gabel V-P: Clinical findings on the use of long-term heavy tamponades (semifluorinated alkanes and their oligomers) in complicated retinal detachment surgery. Graefes Arch Clin Exp Ophthalmol 2002; 240: 965–971.
50.
Fernandez-Bueno I, Pastor JC, Gayoso MJ, Alcalde I, Garcia MT: Müller cells modifications after interact with macrophage-like cells in an organotypic culture of porcine neuroretina. Invest Ophthalmol Vis Sci 2008; 49: 4886–4886.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.